TREM1 and inflammatory bowel disease: Following further analysis, five DEGs (SELE, TREM1, AQP9, FPR2, and HCAR3) were significantly upregulated in the IBD patients who do not respond to infliximab treatment, serving as potential biomarkers for infliximab resistance.